Incyte’s previously disclosed phase 3 win in relapsed or refract | In the phase 3 inMIND study, Monjuvi—added to Bristol ...

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ...

The "Cutaneous T-cell lymphoma - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.The report provides comprehensive insights about 25+ companies and 30+ ...

This is compared to 83% ... Combination Targeted Treatment Produces Lasting Remissions in People With Resistant Aggressive B-Cell Lymphoma June 19, 2024 — Researchers have developed a non ...

Itchy armpits are often caused by non-cancerous conditions, such as poor hygiene or dermatitis. However, in some cases, the ...

Research published by COTA alongside the Memorial Sloan Kettering Cancer Center found patients who start treatment within two ...

Innate Pharma's cancer programs, including partnerships with big pharma, show promise. Find out why IPHA stock could offer ...

HanX Biopharmaceuticals is planning a Hong Kong listing to fund the phase 2 trial of its lead solid tumor drug. | HanX ...

Researchers from Children's Hospital of Philadelphia (CHOP) have discovered the underlying biology that identifies a subset ...

Adcendo joins a growing group of biotechs working to usher the next generation of antibody-drug conjugates to the market.

Those concerned about their cancer risks should speak with medical professionals to figure out what testing protocols to follow.

Cutaneous T cell lymphoma is a rare, difficult to diagnose malignancy of T cells. Malignant T cells, together with populations of stromal cells and B cells, shape their own tumor niche for ...